CytomX Therapeutics price target raised to $3 from $2 at Wedbush

Wedbush raised the firm’s price target on CytomX Therapeutics (CTMX) to $3 from $2 and keeps a Neutral rating on the shares after the company reported Q3 results and said its key efforts remain on track. CytomX continues to expect Phase 1a dose escalation data for CX-904 in the first half of 2024 and the company and co-development partner Amgen (AMGN) expect to potentially initiate expansion cohorts in 2024, the analyst tells investors.